By increasing the expression of OPG and BMP-2, GB4-BPL@siCXCR2/pPTEN could enhance the ability of Enz to inhibit bone resorption, promote bone formation, reduce tibial osteolytic lesions in prostate cancer and enhance bone protection. Here, BMP2 is linked to prostate cancer.